Degarelix

Limits on what this shows

• Key negative/null findings: Explicitly null at the functional level: "There was no change in mitochondrial function measured ex vivo or in vivo after six months of ADT," despite proteomic pathway downregulation. This null finding is carried forward deliberately as required counter-evidence.
• At-risk subgroups: None identified specific to degarelix; the source study found baseline mitochondrial function predicted preservation of physical performance, suggesting lower-baseline-function patients may be more vulnerable, but this was not stratified by drug.

Regulatory status

Not addressed in the FIRMAGON label.

Population evidence

Longitudinal observational study, prostate cancer patients starting ADT, n=59 at baseline (55 at 6 months); mitochondrial proteomic/functional subset n=19. 93.2% of the cohort received a GnRH agonist; degarelix was not specifically named as present in this cohort.

Mechanism

Plausible by extrapolation: castration-level testosterone suppression is the shared endpoint between GnRH agonists and degarelix (an antagonist), so a mitochondrial signal seen with agonist-based ADT is mechanistically plausible for degarelix, though the two drug classes act on the GnRH receptor in opposite ways (agonist-then-desensitization vs. immediate antagonism) and degarelix has not been studied on this endpoint directly.

Counter-evidence held on record

Counter-evidence on record The same study's direct functional measurements (Seahorse ex vivo respiration; in vivo ATP Max by MRS) showed no significant change at 6 months, which weighs against a clinically meaningful mitochondrial-burden effect over that time frame, at least for GnRH agonists. Framing caution This is a GnRH-agonist cohort, not degarelix; graded yellow on class-level plausibility only, per Hard Rule for Tier C evidence, and explicitly not upgradeable to orange or red without a degarelix-specific study.

Limits on what this shows

• Key negative/null findings: Treatment-naive patients had significantly higher nitric oxide values than ADT-treated patients (P=.05), a partial finding running counter to a simple "ADT worsens all oxidative markers" reading; this is carried forward as required counter-evidence.
• At-risk subgroups: Longer ADT duration was associated with higher MDA in this cohort (dose-of-time relationship), consistent with the duration-linked pattern seen in the gut-microbiome entry above.

Regulatory status

Not addressed in the FIRMAGON label; no oxidative-stress or antioxidant marker is mentioned anywhere in the label.

Population evidence

Case-control study, Nigeria: 120 prostate cancer patients (split into treatment-naive and ADT-treated subgroups) versus 100 apparently healthy controls. ADT-treated patients had significantly higher total plasma peroxide (P=.005), oxidative stress index (P=.005), malondialdehyde/MDA (P=.011), and nitric oxide/NO (P=.0001) than controls. A significant positive correlation was found between MDA and duration of ADT treatment (r=0.280, P=.018). Treatment-naive patients also had significantly lower total antioxidant capacity (TAC) than controls (P=.013).

Mechanism

Plausible by extrapolation only: castration-level testosterone suppression is associated with increased visceral adiposity (this cohort's ADT-treated group had a significantly higher waist-hip ratio, P=.0001) and metabolic disturbance, both linked in general physiology to a shift toward pro-oxidant status; the mechanism is not named or isolated as degarelix-specific or GnRH-antagonist-specific in this source, and the specific ADT agents used (GnRH agonist, antagonist, antiandrogen, or orchiectomy) are not stated in the accessible abstract.

Counter-evidence held on record

Counter-evidence on record The study did not name which ADT agents its patients received, so degarelix's inclusion in, or exclusion from, this cohort could not be confirmed either way; this is graded yellow (class-level) rather than orange precisely because of that gap, per this protocol's cohort test. The publisher page (ascopubs.org) returned HTTP 403 and the PMC mirror returned a bot-verification challenge on every fetch attempt this session, so this entry rests on the peer-reviewed abstract record (title, methods, and statistics as indexed by Semantic Scholar and confirmed open-access via Unpaywall) rather than the full text; the full-text methods section, which would state the ADT agents used, was not opened. Framing caution This does not establish that degarelix itself raises oxidative stress markers. No antioxidant supplement or dose is recommended from this entry.

Limits on what this shows

• Why no grade: This revision ran fresh, dedicated searches for this category (WebSearch was unavailable for the same session-wide budget reason as the original review, so all work went through WebFetch). Attempted channels and phrasings: PubMed search-listing pages for "degarelix copper" (returned a reCAPTCHA bot-verification page, not results); the Europe PMC REST API (rate-limited, HTTP 429); the Crossref API with the bibliographic queries "copper zinc status prostate cancer androgen deprivation" and "testosterone suppresses hepcidin iron erythropoietin" (the former returned five results, none addressing copper or zinc micronutrient status; the latter was rate-limited); the OpenAlex works-search endpoint across three separate query phrasings (rate-limited on every attempt); and the Semantic Scholar search, bulk, and title-match endpoints (rate-limited on every attempt). NCBI Bookshelf's own search page refused the request under its robots.txt. Across every channel that returned a substantive answer rather than a block, the result was a genuine negative: no study of any tier measuring copper or ceruloplasmin in ADT or degarelix-treated patients was found. No circulating consumer claim tying degarelix to copper status was identified either. Both conditions for ungraded are met on real search effort, not a single blocked attempt.

Tooling note

Multiple channels were tried and several returned substantive (if negative) results this session; the gap is now evidence-based rather than a zero-attempt tooling gap. A future revision could try a targeted search for copper as an acute-phase reactant in prostate cancer generally (a cancer-indication signal, not a drug effect, per Hard Rule 6) if a copper-specific consumer claim about degarelix ever surfaces.

Limits on what this shows

• Why no grade: This revision ran fresh searches specific to iron and ferritin status (not hemoglobin, which is graded separately above): PubMed search-listing pages for "degarelix iron" (rate-limited, HTTP 429, proxy-blocked from retry); the Europe PMC REST API (rate-limited); the Crossref API with the bibliographic query "iron ferritin status androgen deprivation therapy prostate cancer" (returned five results, none addressing iron metabolism or ferritin, all covering general ADT mechanisms, imaging, or intermittent-versus-continuous dosing instead); the OpenAlex works-search endpoint (rate-limited across multiple phrasings); and the Semantic Scholar search and match endpoints (rate-limited). A plausible physiological mechanism exists in general endocrinology, testosterone is understood to suppress hepcidin, and its loss during ADT could in principle raise hepcidin and restrict iron availability, but no source stating this was successfully opened this session (every attempt to retrieve a testosterone-hepcidin study was rate-limited), so per this protocol's prohibition on citing a source not opened, that mechanism is disclosed here as an unconfirmed lead for a future reviewer, not used as evidence for a grade. No circulating consumer claim specific to degarelix and iron depletion was identified either. Both conditions for ungraded are met on real search effort.

Tooling note

Distinguish this from Oxygen delivery/utilization: the literature located this session on ADT and hemoglobin decline attributes it to reduced erythropoietin-driven erythropoiesis, not iron deficiency, so a future reviewer should not assume the hemoglobin signal implies an iron-status finding. Priority lead for a future revision: confirm and open a testosterone-hepcidin source (rate-limited, not opened, every attempt this session).

Limits on what this shows

• Key negative/null findings: None located; both sources report significant dysbiosis rather than null results. Absence of a degarelix-specific arm is itself a limitation, not a null finding.
• At-risk subgroups: Longer ADT duration was associated with larger microbial shifts in both studies (dose-of-time relationship).

Regulatory status

Not addressed in the FIRMAGON label.

Population evidence

Study 1: 24-week observational study, 23 Japanese prostate cancer patients on ADT (agents unspecified in accessible content); alpha and beta diversity decreased significantly by week 24 (p=0.017 and p<0.001); Proteobacteria, Gammaproteobacteria, Pseudomonadales, and Pseudomonas all increased (p<0.05); Proteobacteria abundance correlated with fecal lactate (R=0.49, p<0.01). Study 2: reanalysis of 56 fecal samples across short/medium/long-term ADT groups (agents not named; degarelix not mentioned); long-term (>33 months) group showed decreased Catenibacterium and Holdemanella and increased Erysipelatoclostridium and Ruminococcus gnavus versus shorter-duration groups.

Mechanism

Named but general: testosterone suppression is proposed to alter gut epithelial and immune signaling and bile-acid handling in ways that shift microbial composition; neither source isolates a degarelix-specific or antagonist-specific pathway distinct from GnRH agonists or orchiectomy.

Counter-evidence held on record

Counter-evidence on record Neither study named degarelix among the ADT agents used, and neither excluded it; the cohort composition could not be confirmed either way in the content accessible this session, which is why this is graded yellow (class-level) rather than orange (drug-specific). Framing caution This does not establish that degarelix itself causes dysbiosis, only that ADT as a class is repeatedly associated with it. No probiotic species or dose is recommended from this entry.

Limits on what this shows

• Key negative/null findings: "There was no change in mitochondrial function measured ex vivo or in vivo after six months of ADT" applies equally to the ATP Max endpoint; this null result is the central finding for this entry, not an incidental note.
• At-risk subgroups: None identified specific to degarelix.

Regulatory status

Not addressed in the FIRMAGON label.

Population evidence

Same longitudinal cohort as the mitochondrial-burden entry (n=59 to 55 over 6 months); baseline ATP Max was positively associated with 6-minute walk distance, VO2 peak, and quality-of-life scores, and negatively associated with BMI, fat mass, and fatigue.

Mechanism

Plausible by extrapolation only: shared testosterone-suppression endpoint with degarelix, distinct receptor mechanism (antagonist vs. agonist), not studied directly in degarelix.

Counter-evidence held on record

Counter-evidence on record This entry is, on balance, a null finding for a 6-month exposure window; it is graded yellow rather than left ungraded because a real (if class-level, non-degarelix) study directly addressed the ATP-production endpoint, satisfying the yellow bar for class extrapolation. Framing caution Do not present this as evidence of an energy-production deficit from degarelix. The best available functional data at 6 months shows no change; longer-exposure or degarelix-specific data could shift this in either direction.

Limits on what this shows

• Key negative/null findings: The degarelix-specific finding is itself the null result for this entry: neither the greater-than-5% nor the 1-to-less-than-5% adverse-reaction table in the current FIRMAGON label lists any hemoglobin, hematocrit, or anemia-related event, arguing against a clinically prominent (symptomatic, treatment-emergent) hematologic effect in degarelix's own 12-month pivotal trial, even though a related regimen from an earlier era showed a measurable hemoglobin decline.
• At-risk subgroups: None identified specific to degarelix; general ADT literature associates longer treatment duration with a larger hemoglobin decline (consistent with the 1-, 2-, and 3-month step-down pattern in the 1997 study), but this has not been confirmed for degarelix itself.

Regulatory status

FIRMAGON label's adverse-reactions tables (reactions occurring at greater than 5%, and separately those at 1% to less than 5%, from the 610-patient degarelix-versus-leuprolide phase III trial) contain no entry for anemia, hemoglobin decreased, hematocrit decreased, or any other hematologic parameter, at either threshold.

Population evidence

Degarelix-specific: FIRMAGON label adverse-reaction tables, n=610 (12-month randomized phase III trial versus leuprolide 7.5mg), Tier A, no hematologic signal reported. Class-level, not degarelix: Strum et al., "Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade," British Journal of Urology, 1997 - hemoglobin fell from a mean baseline of 149 g/L to 139, 132, and 131 g/L at 1, 2, and 3 months respectively in patients on combined hormone blockade (an LHRH-agonist-plus-antiandrogen regimen predating degarelix's 2008 approval; degarelix could not have been in this cohort).

Mechanism

Named for the class-level finding: androgen/testosterone normally stimulates erythropoiesis, and its removal is understood in general endocrinology to reduce erythropoietin-driven red-cell production, producing a mild-to-moderate normocytic anemia; this is a shared endpoint of testosterone suppression regardless of the ADT agent used, making it mechanistically plausible for degarelix, though not degarelix-specific in the source that measured it.

Counter-evidence held on record

Counter-evidence on record The 1997 study's own drug regimen (combined hormone blockade with an antiandrogen, published a decade before degarelix existed) is an active-comparator-free, single-arm-type observation rather than a degarelix comparison, and its patients cannot have received degarelix; the FIRMAGON label's silence on hematologic adverse events in its own 610-patient trial is the more direct, if negative, degarelix-specific evidence, and is why this entry is graded yellow rather than orange. Framing caution This is not evidence that degarelix causes clinically significant anemia. It is a class-level historical signal from an older regimen, bounded by a negative degarelix-specific finding in the current label. No iron or erythropoiesis-stimulating supplement or dose is recommended from this entry; any unexplained hemoglobin drop on degarelix should be evaluated by the prescriber rather than self-treated.